Skip to main content

Updated COVID-19 Vaccine Has Effectiveness of 54 Percent

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 7, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Feb. 6, 2024 -- Updated monovalent COVID-19 vaccines offer vaccine effectiveness (VE) of 54 percent against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to research published in the Feb. 1 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Ruth Link-Gelles, Ph.D., from the CDC in Atlanta, and colleagues analyzed data from the Increasing Community Access to Testing SARS-CoV-2 pharmacy testing program to estimate updated 2023 to 2024 COVID-19 VE against symptomatic SARS-CoV-2 infection with a monovalent XBB.1.5-derived vaccine.

The researchers found that overall VE among adults aged 18 years and older was 54 percent at a median of 52 days after vaccination among 9,222 total eligible tests. VE at 60 to 119 days after vaccination was 49 percent among tests exhibiting spike gene target failure (SGTF) and 60 percent among tests without SGTF in a total of 2,199 tests performed at a laboratory with SGTF testing.

"Vaccination provided protection for infections caused by JN.1 and infections caused by XBB-related lineages. Waning of effectiveness is expected with additional elapsed time since vaccination, especially against less severe disease," the authors write. "All persons aged ≥6 months should stay up to date with COVID-19 vaccination, including receiving a dose of updated vaccine."

One author disclosed ties to Eagle Health Analytics.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

At-School Vaccination Boosts HPV Vaccination Coverage

THURSDAY, May 30, 2024 -- At-school vaccination may be a useful tool to increase human papillomavirus (HPV) vaccination coverage among adolescents, according to a study published...

Mortality Higher for COVID-19 Hospitalization Than for Flu in 2023/2024 Season

WEDNESDAY, May 22, 2024 -- In fall/winter 2023/2024, the risk for death in patients hospitalized for COVID-19 was greater than the risk for death in patients hospitalized for...

Global Life Expectancy, Disease Burden Set to Keep Improving

WEDNESDAY, May 22, 2024 -- Life expectancy and age-standardized disease burden are expected to continue improving between 2022 and 2050, according to the Global Burden of Disease...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.